Free shipping on all orders over $ 500

Atezolizumab

Cat. No. M6101
Atezolizumab Structure
Synonym:

MPDL3280A

Size Price Availability Quantity
5mg USD 513  USD570 In stock
10mg USD 882  USD980 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

In vitro: A key feature of atezolizumab is that it is FcγR-binding deficient, so it cannot bind to Fc receptors on phagocytes and therefore does not cause antibody-dependent cell-mediated cytotoxicity (ADCC). atezolizumab treatment could bring cytokine changes include transient increases in IL-18, IFNγ, and CXCL11, and a transient decrease in IL-6; cellular changes include increases in proliferating CD8+ T cells.

In vivo: By blocking the PD-L1/PD-1 immune checkpoint, atezolizumab reduces immunosuppressive signals found within the tumor microenvironement and consequently increases T cell mediated immunity against the tumor. The pharmacokinetics of atezolizumab were initially studied in cynomolgus monkeys and mice where its volume of distribution was calculated to be approximately that of the plasma volume. The in vivo biodistribution of atezolizumab 24 hours after infusion is, in order of magnitude, the spleen, lungs, kidneys, liver, heart, and muscle. In tumor bearing animals, the drug also accumulates intratumorally, initially at the pushing border of the tumor and progressing later to the tumor core, particularly if the tumor is necrotic. The pharmacokinetic curve of atezolizumab is dose-dependent (non-linear) because of target mediated drug disposition (binding of drug to the PD-L1 ligand in the body). Saturation of PD-L1 receptors by atezolizumab on circulating CD4 and CD8 T cells occurs between 24 and 48 hours after dosing with serum concentrations > 0.5 μg/mL. MPDL3280A binds to PD-L1 in monkey and human with comparable affinity between species.

In contrast, atezolizumab was able to interact with the mPD-L1, block the mPD-L1/hPD-L1 immune checkpoint in a cell-based assay, and provide inhibition of the growth of mouse tumors in a syngeneic mouse model, where the mPD-L1/mPD-1 immune checkpoint is present.

Product Citations
Protocol
Cell Experiment
Cell lines DCCIKs lymphocytes
Preparation method The in vitro cytotoxicity of the DCCIKs used as effector cells in the absence or presence of 5 μg/mL MPDL3280A against CaSki cells employed as target cells at a ratio of 10:1, 30:1 and 90:1 was determined using a CCK8 kit. The effector and target cells were added to 96-well plates and incubated for 24 h. The groups comprising a mixture of cell types were the experimental groups, whereas the control groups contained only one cell type of the CaSki cells, DCCIKs or 1640 RPMI cultivating solution. The CCK8 assay was performed in triplicate and optical density (OD) was read at 570 nm.
Concentrations 5 μg/mL
Incubation time 24 h
Animal Experiment
Animal models Cynomolgus monkeys
Formulation 20 mM his-acetate, 0.02% polysorbate 20, 240 mM sucrose, pH 5.5
Dosages 0.5, 5 and 20 mg/kg
Administration i.v.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight
Formula
CAS Number 1380723-44-3
Purity >98%
Solubility
Storage at -20°C
References

Epstein-Barr virus-encoded circular RNA circBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1
Junshang Ge, et al. Cancer Res. 2021 Jul 28;canres.4321.2020. PMID: 34321242.

Human and mouse PD-L1: similar molecular structure, but different druggability profiles
Katarzyna Magiera-Mularz, et al. iScience. 2020 Dec 24;24(1):101960. PMID: 33437940.

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A, et al. Sci Rep. 2017 Feb 16;7:42687. PMID: 28202921.

PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG, et al. Bioconjug Chem. 2016 Sep 21;27(9):2103-10. PMID: 27458027.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L, et al. Lancet. 2016 Apr 30;387(10030):1837-46. PMID: 26970723.

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Chatterjee S, et al. Oncotarget. 2016 Mar 1;7(9):10215-27. PMID: 26848870.

Related PD-1/PD-L1 Products
BMS-1166

BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor, which binds to human PD-L1 and blocks its interaction with PD-1.

BMS-1001

BMS-1001 is a potent PD-1/PD-L1 interaction inhibitor.

Durvalumab

Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1.

PD1-PDL1 inhibitor 1

PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-Ll protein/protein interaction with IC50 value of 6 nM.

Pembrolizumab

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Atezolizumab, MPDL3280A supplier, PD-1/PD-L1, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.